Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications.

Abstract:

:Monoclonal B-cell lymphocytosis (MBL) is a recently defined medical condition that displays biological similarities to chronic lymphocytic leukemia (CLL), the most common subtype of adult leukemia in the Western world. MBL may be diagnosed in individuals with a normal lymphocyte count via a screening assay (screening MBL) or through the clinical evaluation of lymphocytosis (clinical MBL). Clinical MBL, which resembles CLL with a good prognosis, has attracted considerable interest because of its clinical and biological implications. The biological profile of clinical MBL appears indistinguishable from that of CLL for a large variety of markers. Differential diagnosis between clinical MBL and CLL is mainly based on peripheral blood B-cell counts. The 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria changed the definition of CLL to a B-cell count ≥ 5.0 × 10(9)/L to eliminate overlap between CLL and MBL. However, this cut-off is arbitrary, and recent studies suggest that a B-cell count of 10.0-11.0 × 10(9)/L may represent the threshold that best predicts time to first treatment. After a diagnosis of clinical MBL, patients should be educated about appropriate monitoring and follow-up keeping in mind that, with time and counseling, most patients will understand that clinical MBL and CLL represent a continuum.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Molica S,Mauro FR,Molica M,Del Giudice I,Foà R

doi

10.3109/10428194.2012.666542

subject

Has Abstract

pub_date

2012-09-01 00:00:00

pages

1660-5

issue

9

eissn

1042-8194

issn

1029-2403

journal_volume

53

pub_type

杂志文章,评审
  • Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.

    abstract::Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diag...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.963080

    authors: Movassaghian M,Brunner AM,Blonquist TM,Sadrzadeh H,Bhatia A,Perry AM,Attar EC,Amrein PC,Ballen KK,Neuberg DS,Fathi AT

    更新日期:2015-06-01 00:00:00

  • Comparison of bone marrow aspirates and biopsies in pediatric patients with ALL at days 7 and 14 of induction therapy.

    abstract::The percentage of blasts in the bone marrow aspirates at day 7 or 14 of induction therapy in pediatric ALL patients is an indicator of rapid early response and an independent prognostic factor for long term outcome. Discrepancies between the percentages of blasts in bone marrow aspirates compared to biopsies have been...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001625863

    authors: Countouriotis A,Landaw EM,Naeim F,Moore TB,Sakamoto KM

    更新日期:2004-04-01 00:00:00

  • Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia.

    abstract::Speed of response to therapy predicts outcome in childhood lymphoblastic leukaemia. This observation has been made studying both blood and bone marrow in children on widely differing treatment regimens from the 1970s to the present day. It appears to be independent of other classical prognostic factors such as age and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057609

    authors: Lilleyman JS

    更新日期:1998-11-01 00:00:00

  • Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina.

    abstract::The aim of this study was to evaluate the influence of the most common genetic variants in methylenetetrahydrofolate reductase (MTHFR), thiopurine methyltransferase (TPMT) and glutathione-S-transferases (GSTs) on the outcome of acute lymphoblastic leukemia (ALL) treatment in Argentinean children. Two hundred and eight...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.951844

    authors: Aráoz HV,D'Aloi K,Foncuberta ME,Sanchez La Rosa CG,Alonso CN,Chertkoff L,Felice M

    更新日期:2015-05-01 00:00:00

  • Bone marrow aplasia with prominent atypical plasmacytic proliferation preceding acute lymphoblastic leukemia.

    abstract::A two-year-old boy presented with pancytopenia. Bone marrow examination revealed an aplastic marrow with prominent immature plasma cell proliferation, which mimicked plasma cell leukemia. Immunohistochemistry, however, revealed a polyclonal population consistent with a reactive process, excluding plasma cell neoplasia...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145722

    authors: Kikuchi M,Ohsaka A,Chiba Y,Sato M,Muraosa Y,Hoshino H

    更新日期:1999-09-01 00:00:00

  • Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

    abstract::Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1251592

    authors: Finnes HD,Chaffee KG,Call TG,Ding W,Kenderian SS,Bowen DA,Conte M,McCullough KB,Merten JA,Bartoo GT,Smith MD,Leis J,Chanan-Khan A,Schwager SM,Slager SL,Kay NE,Shanafelt TD,Parikh SA

    更新日期:2017-06-01 00:00:00

  • Serum interleukin-6 levels in patients with thrombocytosis.

    abstract::Interleukin-6 (IL-6) has been shown to increase platelet counts in several animal models and to enhance megakaryocytopoiesis in vitro. In order to investigate the possible relationship between IL-6 and thrombocytosis, serum IL-6 levels in patients with platelet counts > or = 6 x 10(5)/microliters were measured using a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209054910

    authors: Hollen CW,Henthorn J,Koziol JA,Burstein SA

    更新日期:1992-10-01 00:00:00

  • Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

    abstract::Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1457147

    authors: Pleyer C,Wiestner A,Sun C

    更新日期:2018-12-01 00:00:00

  • Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma.

    abstract::Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1334121

    authors: Chao C,Silverberg MJ,Chen LH,Xu L,Martínez-Maza O,Abrams DI,Zha HD,Haque R,Said J

    更新日期:2018-02-01 00:00:00

  • Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.

    abstract::FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which is designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), FB2 significantly inhibited the growth of imatinib-resistant cell lines of different resistance mechanisms (K562/G5.0 and K562/G01), and decreased the expression of aut...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802709438

    authors: Liu H,Li H,Feng Z,Tai J,Meng Y,Wang H,Xin H,Zhang S,Zuo M,Zhang Y,Chen X

    更新日期:2009-03-01 00:00:00

  • Expression of sialosyl-T and disialosyl-T antigens in erythroid cells.

    abstract::Expression of T, sialosyl-T and disialosyl-T antigens on normal blood and bone marrow cells as well as transformed cells was examined using specific monoclonal antibodies and multidimensional flow cytometry. Both anti-sialosyl-T (QSH1) and anti-disialosyl-T (QSH2) monoclonal antibodies aggregated erythrocytes. The ant...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709039027

    authors: Muroi K,Amemiya Y,Sievers EL,Miura Y,Hakamori SI,Loken MR

    更新日期:1997-05-01 00:00:00

  • Role of the leukemia-associated transcription factor STAT3 in platelet physiology.

    abstract::Actinomycin D, a transcriptional inhibitor, was found to inhibit platelet potentiation by thrombopoietin (TPO), suggesting that TPO stimulation of platelets involves mitochondrial transcription. We sought to determine a possible role for leukemia-associated signal transducers and activators of transcription (STAT) pro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819022386716

    authors: Vassilev AO,Lorenz DR,Tibbles HE,Uckun FM

    更新日期:2002-07-01 00:00:00

  • Expression of c-kit receptor (CD117) and CD34 in leukemic cells.

    abstract::The expression of c-kit receptor (c-kit R; CD117) and CD34 was examined in acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML) in blastic transformation (BT), and myelofibrosis (MF) in myeloid BT. In myeloid leukemia including AML, CML-myeloid BT and MF-myeloid BT, both c-kit R ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509049769

    authors: Muroi K,Nakamura M,Amemiya Y,Suda T,Miura Y

    更新日期:1995-01-01 00:00:00

  • Coexistent multiple myeloma and myelofibrosis.

    abstract::Although the association of bone marrow fibrosis with plasma cell dyscrasias has already been described in several reports, the close relationship between these entities still remains unclear. In this report we describe a patient with clinical and pathologic findings which initially suggested a diagnosis of myelofibro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148567

    authors: Pulsoni A,Bianco P,La Verde G,Mecarocci S,Petrucci MT,Torromeo C,Avvisati G

    更新日期:1993-07-01 00:00:00

  • Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas.

    abstract::Akt (protein kinase B) is a serine/threonine kinase involved in the regulation of cell survival signals. Akt is expressed in T- and B-lymphocytes and is activated in response to cytokine and antigen-receptor stimulation. Three isoforms of Akt have been identified, Akt-1, -2 and -3, but the expression pattern and speci...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500159944

    authors: Fillmore GC,Wang Q,Carey MJ,Kim CH,Elenitoba-Johnson KS,Lim MS

    更新日期:2005-12-01 00:00:00

  • The role of intensive chemotherapy in myelodysplastic syndromes.

    abstract::We review results of intensive chemotherapy (IC) obtained in myelodysplastic syndromes (MDS). Overall, the complete remission (CR) rates and median CR duration obtained with IC are low in MDS, especially when compared to results obtained in de novo AML treated with the same chemotherapy regimens; very few MDS patients...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209049816

    authors: Fenaux P,Preudhomme C,Hebbar M

    更新日期:1992-09-01 00:00:00

  • A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.

    abstract::CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituxima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/10428194.2019.1643463

    authors: Andritsos LA,Byrd JC,Cheverton P,Wu J,Sivina M,Kipps TJ,Burger JA

    更新日期:2019-12-01 00:00:00

  • Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures.

    abstract::Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with an association with inflammation and viral infections. We hypothesize that environmental factors may be involved in the pathogenesis of DLBCL. In this study, we compared gene expression profiles of lymph node tissues from patients with DLBCL from tw...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.738365

    authors: Högfeldt T,Bahnassy AA,Kwiecinska A,Osterborg A,Tamm KP,Porwit A,Zekri AR,Lundahl J,Khaled HM,Mellstedt H,Moshfegh A

    更新日期:2013-05-01 00:00:00

  • Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data.

    abstract::There is little evidence about whether additional risk stratification for adult patients with acute lymphoblastic leukemia age 65 and older is warranted. Using the Surveillance, Epidemiology, and End Results data linked to Medicare claims, we examined the effects of age, comorbid conditions, and mobility limitations o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1555329

    authors: Danese MD,Katz A,Cetin K,Chia V,Gleeson ML,Kelsh M,Griffiths RI

    更新日期:2019-08-01 00:00:00

  • Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia.

    abstract::One of the possible causes of treatment failure in acute leukemia is the emergence of multidrug resistance caused by P-glycoprotein (P-gp) overexpression. We compared a flow cytometric assay using JC-1 with a technique using rhodamine 123 (rho123) to evaluate the P-gp function in acute leukemia. Samples from 50 acute ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190412331272767

    authors: Swerts K,de Moerloose B,Dhooge C,Noens L,Laureys G,Benoit Y,Philippé J

    更新日期:2004-11-01 00:00:00

  • A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.

    abstract::The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders. Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway. A cell line hom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701607576

    authors: Bareng J,Jilani I,Gorre M,Kantarjian H,Giles F,Hannah A,Albitar M

    更新日期:2007-11-01 00:00:00

  • Immunophenotypes and Gene Rearrangements of the T-Cell Receptor in Two Patients with a Large Granular Lymphocyte Disorder.

    abstract::Large granular lymphocyte disorder (LGLD) is a lymphoproliferative disease, characterized by moderate lymphocytosis with an excess of large granular lymphocytes, neutropenia, anemia, and a variable, but mostly chronic clinical course. We describe two patients with LGLD. One patient presented with symptomatic corticost...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109064883

    authors: Peller S,Kaufman S,Rotter V

    更新日期:1991-01-01 00:00:00

  • Extranodal adult T-cell leukemia/lymphoma of the head and neck: a clinicopathological study of nine cases and a review of the literature.

    abstract::Extranodal adult T-cell leukemia/lymphoma (ATLL) of the head and neck is a rare disease. We studied the clinicopathological features of nine patients with ATLL involving extranodal head and neck sites and conducted a literature review. Six patients presented with extranodal mass of the head and neck, whereas three had...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802702383

    authors: Miyagi T,Nagasaki A,Taira T,Shinhama A,Suzuki M,Ohshima K,Takasu N

    更新日期:2009-02-01 00:00:00

  • Lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 expression on B-cell subsets and the effects of splenectomy-experimental studies.

    abstract::There is an abundance of data dealing with recirculation of T cells in the rats, but relatively little is known about the traffic of B cells. The adhesion molecules expressed on the surface membrane are of great significance for recirculation of lymphocytes. However, very little is known about the expression of variou...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000033006

    authors: Milićević NM,Milićević Z,Westermann J

    更新日期:2002-11-01 00:00:00

  • Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution.

    abstract::Peripheral T-cell lymphomas are characterized by a poor clinical outcome. We retrospectively analyzed 208 adults treated in our institution between 2000 and 2011. Median age at diagnosis was 55 years. Fifty-one percent had B symptoms and 51% serum elevated lactate dehydrogenase (LDH) levels. Eastern Cooperative Oncolo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.776680

    authors: Broussais-Guillaumot F,Coso D,Belmecheri N,Ivanov V,Schiano de Collela JM,Aurran-Schleinitz T,Stoppa AM,Chetaille B,Xerri L,Esterni B,Blaise D,Bouabdallah R

    更新日期:2013-11-01 00:00:00

  • Analysis of Wilms tumor gene (WT1) expression in acute leukemia patients with special reference to the differential diagnosis between eosinophilic leukemia and idiopathic hypereosinophilic syndromes.

    abstract::Continuous Wilms' tumor gene (WT1) expression is a typical feature of leukemic blasts in AML, ALL, and blast crisis CML patients. It is easily detectable by a variety of RT-PCR protocols, which differ mainly in their sensitivity. The nuclear WT1 protein can be found in blasts of approximately 50-60% of acute leukemia ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009148849

    authors: Menssen HD,Schmidt A,Bartelt S,Arjomand A,Thomsen H,Leben R,Kath R,Thiel E

    更新日期:2000-01-01 00:00:00

  • The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for 'a lymphoma stem cell'.

    abstract::Monitoring of t(14;18) in blood or bone marrow in follicular lymphoma (FL) remains controversial. We attempted to monitor t(14;18) in lymph nodes by ultrasound-guided fine needle aspirations (UG-FNA). First, we confirmed t(14;18) in 27/31 UG-FNAs of lymph nodes with fluorescent in situ hybridisation (FISH) and/or poly...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902927005

    authors: Janikova A,Mayer J,Kren L,Smardova J,Dvorakova D,Neubauer J,Vasova I

    更新日期:2009-07-01 00:00:00

  • Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients.

    abstract::B lymphocytes from the peripheral blood of patients with chronic lymphocytic leukaemia (CLL) were analysed for the nuclear presence and DNA binding of a panel of transcription factors which are involved in the gene control of lymphoid cells. The following transcription factors were studied: the Octamer factors Oct-1 a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609054868

    authors: Schuh K,Avots A,Tony HP,Serfling E,Kneitz C

    更新日期:1996-11-01 00:00:00

  • Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.

    abstract::PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-daily PTK787/ZK222584 at a target dose of 1250 mg. Eighteen patien...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.784969

    authors: Brander D,Rizzieri D,Gockerman J,Diehl L,Shea TC,Decastro C,Moore JO,Beaven A

    更新日期:2013-12-01 00:00:00

  • The involvement of adhesion molecules in the biology of multiple myeloma.

    abstract::Multiple myeloma represents a B cell malignancy characterized by a monoclonal proliferation of plasma cells. A striking feature of the disease is the tendency of the malignant plasma cells to affect mainly the bone marrow environment and to invade the peripheral blood only in the terminal stage. The growth of myeloma ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309145751

    authors: Van Riet I,Van Camp B

    更新日期:1993-04-01 00:00:00